World Pain Relieving Drug Market 2012-2022


August 8, 2012
235 Pages - SKU: VSG4881895
License type:
Countries covered: Global

World Pain Relieving Drug Market 2012-2022

  enlarge


See what the future holds for painkillers. Visiongain's report gives you revenue predictions to 2022. You find data, trends, opportunities and commercial prospects.

That new study lets you assess forecasted sales at overall world market, submarket, product and national level. You see why the pain relievers industry and market will grow, as we predict.

In our investigation you find revenue forecasting, growth rates and market shares. Also, you see qualitative analyses, R&D and commercial developments. You receive 79 tables, 74 charts and two research interviews.

The following sections highlight what you discover in the report.

Prospects for submarkets and products

In addition to analyses of the overall world market, you see revenue forecasting of five world-level submarkets to 2022:
  • Narcotics
  • Non-narcotics
  • Neuropathic pain relievers
  • Treatments for migraines
  • Treatments for arthritis.
Also, you see how 28 leading drugs - including Oxycontin ER, Panadol, Lyrica and Zomig - can perform to 2022. Our study includes OTC (over-the-counter) and Rx (prescription) pain relieving medicines. There, you find revenue forecasts and other data.

The work also breaks the overall world market into leading national markets.

Prospects for leading countries shown to 2022

Developments worldwide will influence the market, especially fast-rising demand in emerging countries. There will be many opportunities for pain-treating products.

You discover revenue forecasts to 2022 for nine national markets:
  • US
  • Japan
  • Germany, France, UK, Italy and Spain (EU5 nations)
  • India and China.
This decade, revenues from India and China will be among the fastest growing worldwide. In particular, product launches from 2012 onwards will benefit regional and national markets.

Research and development activities

What's happening in the R&D pipeline for painkillers? You see developmental trends there:
  • Narcotic drugs
  • Non-narcotic products
  • Neuropathic treatments
  • Anti-migraine agents
  • Arthritic pain relievers.
Discover how technological progress changes the sector. Our investigation explains, bringing together many issues.

Prominent issues affecting the pain treatment sector

Our study lets you assess industry trends and outlooks worldwide from 2012. As the work shows, many issues affect the industry and market:
  • Better treatment of acute and chronic pain worldwide, including cancer pain
  • Anticonvulsants, analgesics, COX-2 inhibitors, novel opioids, cannabinoids and local anaesthetics
  • Non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids and aldose reductase inhibitors
  • Disease modifying anti-rheumatic drugs (DMARDs)
  • Biologics (e.g. monoclonal antibodies, MAbs) for rheumatoid arthritis (RA)
  • Reimbursement, regulations, patent expiries, generic competition and OTC switching.
You see discussions of technological, commercial and economic matters, with emphasis on organisations competing in the industry.

Discussions of leading companies and prospects for market growth

What will happen next? The pharmaceutical industry will improve treatments for pain relief and increase revenues there from 2012 to 2022. The R&D pipeline is strong.

Overall world revenue for that market area will reach $61.6bn in 2012, our report forecasts. Ageing populations and diseases such as cancer, arthritis and diabetes will increase sales of painkillers. Also, improved drug delivery and new formulations will be important.

You find discussions of Pfizer, GSK, Johnson & Johnson, Bristol-Myers Squibb and other developers and manufacturers. Also, you see our interviews with two companies. This decade, many opportunities will arise.

Eight ways World Pain Relieving Drug Market 2012-2022 benefits you

In particular, then, our study gives you the following knowledge on painkilling drugs:
  • Forecasted revenues to 2022 for the overall world market and submarkets
  • Potential revenues of 28 leading products to 2022
  • Market forecasting to 2022 for the US, Japan, leading EU countries (Germany, France, the UK, Italy and Spain), India and China
  • Assessment of companies - discussions of activities and outlooks
  • Review of R&D pipelines by treatment area - progress and trends
  • Opinions on the sector, including our research interviews with leaders in industry
  • Investigation of competition and opportunities influencing sales
  • Discussion of what stimulates and restrains the industry and market.
That work gives independent analyses from our primary and secondary research. You receive information found only in our report.

With our study, you find business intelligence to help you understand the future of that industry and market.

Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

The publisher is using a password system to access all reports. This password will be set up for single user and departmental licenses and will be emailed out to the client at the same time as the report. In the case of departmental site license purchases, the publisher requires all email addresses for the licensed users prior to fulfillment.


Additional Information


Report Excerpt

6.8.2 Nucynta ER Sales Forecast, 2012-2022

The global sales for Nucynta ER in 2011 were estimated at $51m. Nucynta ER was launched in 2011 and will achieve strong sales throughout the forecast period. Visiongain believes it will reach blockbuster status by 2017, with a CAGR of 65.4% from 2011-2017 (Table 6.11 and Figure 6.10). Nucynta ER’s success will be driven by its efficacy in both neuropathic and nociceptive pain conditions. As a result, it is expected to be prescribed for conditions involving both pain types, such as chronic lower back pain. Its opioid-sparing effects and reduced potential for abuse will also be key clinical advantages for Nucynta ER in neuropathic pain conditions that require long-term management. In addition the experience of Johnson and Johnson within the US pain market will increase sales in the US.

Companies Listed

AB Science
Abbott Laboratories
AcelRx Pharmaceuticals
Actavis
Acura Pharmaceuticals
Allergan
Almirall
Alpharma
ALZA Corporation
American Council for Headache Education
Amgen
Anesiva
Aoxing Pharmaceuticals
Apotec
Apotex
Arcion Therapeutics
Astellas Pharma
AstraZeneca
Avanir Pharmaceuticals
Bayer
BioDelivery Sciences
Biogen Idec
Biovail Corporation
Bristol-Myers Squibb
Britannia Pharmaceuticals
CeNeS Pharmaceuticals
Centocor Ortho Biotech
China Aoxing
CK Life Sciences
Collegium Pharmaceutical
CoLucid Pharmaceuticals
Dainippon
Dara Biosciences
Depomed
Descartes Therapeutics
Dr. Reddy's Laboratories
Durect
Eisai
Eli Lilly
Endo Pharmaceuticals
EpiCept
European Medicines Agency (EMA)
Food and Drug Administration (FDA)
Forest Pharmaceuticals
Galderma
Genentech
Genmab
GlaxoSmithKline (GSK)
Grünenthal
Horizon Pharma
Human Genome Sciences
Insys Therapeutics
International Association for the Study of Pain (IASP)
Ipsen
IVAX Pharmaceuticals
Janssen Pharmaceuticals
Johns Hopkins University
Johnson and Johnson (J&J)
King Pharmaceuticals
Ligand Pharmaceuticals
Lundbeck
MAP Pharmaceuticals
Merck & Co.
Merck Serono
Mitsubishi Tanabe Pharma
Mylan
National Health Service (NHS)
National Institute for Health and Clinical Excellence (NICE)
Nektar Therapeutics
NeurAxon
NeurogesX
Neurotune
Newron Pharmaceuticals
NicOx Pharmaceuticals
Novartis
NuPathe
Nuvo Research
Omeros
Ono Pharmaceutical
Organon
Ortho-McNeil
Pacira Pharmaceuticals
Pain Therapeutics
Paion
Par Pharmaceuticals
Penwest
Pfizer
Pharmacia
PLx Pharma
Pozen
PriCara Pharmaceuticals
Procter & Gamble
Proteus
Purdue Pharma
QRxPharma
Ranbaxy
Ratiopharm
Rigel Pharmaceuticals
Roche
Schering Plough
Shire
SkyePharma
Solvay Pharmaceuticals
Spinifex Pharmaceuticals
Stada Pharmaceuticals
Sun Pharmaceuticals
Syntaxin
Takeda
Teikoku
Teva Pharmaceutical Industries
The Arthritis Foundation
The International Diabetes Federation (IDF)
The Neuropathy Association
The World Health Organization (WHO)
UCB
University of Queensland
US Census Bureau
US Society for Neuroscience
US WorldMeds
Valeant Pharmaceuticals International
Watson Pharmaceuticals
WEX Pharmaceuticals
Wyeth (now part of Pfizer)
Xenoport
Zars Pharmaceuticals
Zenyaku Kogyo
Zogenix

More Global CNS/Neurology reports

Global Deep Brain Stimulator Market 2012-2016 by Infiniti Research Limited
Global Deep Brain Stimulator Market 2012-2016 TechNavio's analysts forecast the Global Deep Brain Stimulator market to grow at a CAGR of 16.99 percent over ...
Anorexia Nervosa Global Clinical Trials Review, H1, 2013 by GlobalData
Anorexia Nervosa Global Clinical Trials Review, H1, 2013SummaryGlobalData's clinical trial report, “Anorexia Nervosa Global Clinical Trials Review, H1, 2013 provides data on the Anorexia Nervosa ...
Dyslexia Global Clinical Trials Review, H1, 2013 by GlobalData
Dyslexia Global Clinical Trials Review, H1, 2013SummaryGlobalData's clinical trial report, “Dyslexia Global Clinical Trials Review, H1, 2013 provides data on the Dyslexia clinical trial scenario. ...
Disease and Therapy Review: Generalized Anxiety Disorder (GAD) by Timely Data Resources, Inc.
The Generalized Anxiety Disorder (GAD) Disease and Therapy Review provides an overview of the disease and related conditions, with prevalence numbers and percentages for major ...
See all reports like this >>